Replies to post #29940 on Marker Therapeutics Inc (MRKR)

[Investor_cmz]

Thanks for your input. I don’t understand how only 1 PT could meet primary endpoint if the median PFS and OS were significantly longer than 10 weeks ?

[rwwest]

Are you claiming that CR was a "primary outcome"? Below from Clinical Trial website-
Primary Outcome Measures :

1) Number of patients with treatment related serious adverse events [ Time Frame: 7 months ]
To determine the safety of up to 6 intravenous infusions of multiTAA-specific T cells in pancreatic cancer patients with metastatic, locally advanced unresectable, or resectable disease.

2) Number of patients who received 6 infusions of multiTAA-specific T cells [ Time Frame: 6 months ]
To determine the feasibility of completing a total of 6 intravenous infusions of multiTAA-specific T cells to pancreatic cancer patients with metastatic, locally advanced unresectable, or resectable disease


Secondary Outcome Measures :

1) Progression Free Survival using the Kaplan-Meier method [ Time Frame: 5 years ]
To evaluate the progression-free of patients after multiTAA-specific T cell infusions

2) Overall Survival using the Kaplan-Meier method [ Time Frame: 5 years ]
To evaluate the overall survival of patients after multiTAA-specific T cell infusions
---------------------------------------------------------
There has been a lot of hope expressed for another CR, but that's just what some people would like to see.